522 related articles for article (PubMed ID: 26402157)
1. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
[TBL] [Abstract][Full Text] [Related]
2. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
3. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
J Nucl Med; 2016 Jun; 57(6):936-42. PubMed ID: 26848176
[TBL] [Abstract][Full Text] [Related]
4. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
5. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
7. Stability and Biodistribution of Thiol-Functionalized and (177)Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles.
Yook S; Lu Y; Jeong JJ; Cai Z; Tong L; Alwarda R; Pignol JP; Winnik MA; Reilly RM
Biomacromolecules; 2016 Apr; 17(4):1292-302. PubMed ID: 26974228
[TBL] [Abstract][Full Text] [Related]
8.
Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
[TBL] [Abstract][Full Text] [Related]
9. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to
Aghevlian S; Cai Z; Lu Y; Hedley DW; Winnik MA; Reilly RM
Mol Pharm; 2019 Feb; 16(2):768-778. PubMed ID: 30589553
[TBL] [Abstract][Full Text] [Related]
11. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
12. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
Reilly RM; Kiarash R; Cameron RG; Porlier N; Sandhu J; Hill RP; Vallis K; Hendler A; Gariépy J
J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315
[TBL] [Abstract][Full Text] [Related]
13. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy.
Fonge H; Lee H; Reilly RM; Allen C
Mol Pharm; 2010 Feb; 7(1):177-86. PubMed ID: 19924993
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.
Jiménez-Mancilla N; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Isaac-Olivé K; Camacho-López M; Torres-García E
J Labelled Comp Radiopharm; 2013 Nov; 56(13):663-71. PubMed ID: 25196028
[TBL] [Abstract][Full Text] [Related]
16. Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with
Lai P; Cai Z; Pignol JP; Lechtman E; Mashouf S; Lu Y; Winnik MA; Jaffray DA; Reilly RM
Phys Med Biol; 2017 Oct; 62(22):8581-8599. PubMed ID: 29077574
[TBL] [Abstract][Full Text] [Related]
17. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer.
Chattopadhyay N; Cai Z; Pignol JP; Keller B; Lechtman E; Bendayan R; Reilly RM
Mol Pharm; 2010 Dec; 7(6):2194-206. PubMed ID: 20973534
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting,
Aghevlian S; Cai Z; Hedley D; Winnik MA; Reilly RM
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):22. PubMed ID: 33169241
[TBL] [Abstract][Full Text] [Related]
20. Relative Biological Effectiveness (RBE) of [
Boyle AJ; Cai Z; O'Brien S; Crick J; Angers S; Reilly RM
Nucl Med Biol; 2023; 122-123():108367. PubMed ID: 37506639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
